AIGH Capital Management LLC Purchases 20,300 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

AIGH Capital Management LLC boosted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 9.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 224,713 shares of the company's stock after buying an additional 20,300 shares during the quarter. Tarsus Pharmaceuticals makes up about 3.9% of AIGH Capital Management LLC's investment portfolio, making the stock its 10th largest position. AIGH Capital Management LLC owned 0.59% of Tarsus Pharmaceuticals worth $12,442,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of TARS. Intech Investment Management LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter worth approximately $282,000. Charles Schwab Investment Management Inc. raised its position in Tarsus Pharmaceuticals by 10.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 290,009 shares of the company's stock valued at $9,538,000 after purchasing an additional 28,130 shares during the last quarter. FMR LLC boosted its stake in Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after purchasing an additional 3,537 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Tarsus Pharmaceuticals by 10.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,835 shares of the company's stock worth $1,935,000 after purchasing an additional 5,709 shares during the last quarter. Finally, Verition Fund Management LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the third quarter valued at $763,000. 90.01% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of brokerages have commented on TARS. HC Wainwright reissued a "buy" rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Jefferies Financial Group increased their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. Guggenheim restated a "buy" rating and issued a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Oppenheimer increased their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Finally, Barclays dropped their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $63.67.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, General Counsel Bryan Wahl sold 3,341 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the completion of the sale, the general counsel now owns 58,057 shares in the company, valued at $2,687,458.53. This represents a 5.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Dianne C. Whitfield sold 2,315 shares of Tarsus Pharmaceuticals stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $107,161.35. Following the transaction, the insider now owns 50,751 shares in the company, valued at approximately $2,349,263.79. This represents a 4.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,542 shares of company stock valued at $1,581,173. Corporate insiders own 8.25% of the company's stock.

Tarsus Pharmaceuticals Trading Down 5.3 %

Shares of NASDAQ:TARS traded down $2.74 during midday trading on Thursday, hitting $48.75. The company had a trading volume of 185,672 shares, compared to its average volume of 661,540. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28. The firm has a fifty day simple moving average of $49.21 and a 200 day simple moving average of $46.48. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -12.80 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.08. The company had revenue of $66.41 million during the quarter, compared to analyst estimates of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. On average, analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.